BMS-863233
Advanced Solid Cancers
Bristol-Myers SquibbSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Advanced Solid Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FENTANYL Gachon University Gil Medical Center | Phase 2 | B |
prl3-zumab Intra-IMMUSG Pte Ltd | Phase 2/3 | B |
Oxycodone Gachon University Gil Medical Center | Phase 2 | B |
Zalifrelimab Agenus Inc. | Phase 1/2 | CCC |
Inv-6452 Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | CC |
View all 22 →
Same molecule, other indications
BMS-863233 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →